Douglas A. Dyer
Vorstandsvorsitzender bei Grace 3, Inc.
Profil
Douglas A.
Dyer is currently the President, Chief Executive & Financial Officer at Grace 3, Inc. He was previously the President & Director at Q Therapeutics, Inc. in 2011.
Aktive Positionen von Douglas A. Dyer
| Unternehmen | Position | Beginn |
|---|---|---|
Grace 3, Inc.
 Grace 3, Inc. Financial ConglomeratesFinance Grace 3, Inc. operates as a blank check company. It is a development stage company and serves as a vehicle to effect a merger, exchange of capital stock, and asset acquisition. The company was founded on October 27, 2005 and is headquartered in Red Bank, NJ. | Vorstandsvorsitzender | 23.09.2009 |
Ehemalige bekannte Positionen von Douglas A. Dyer
| Unternehmen | Position | Ende |
|---|---|---|
Q Therapeutics, Inc.
 Q Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman in March 2002 and is headquartered in Salt Lake City, UT. | Finanzdirektor/CFO | 04.07.2011 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Grace 3, Inc.
Grace 3, Inc. Financial ConglomeratesFinance Grace 3, Inc. operates as a blank check company. It is a development stage company and serves as a vehicle to effect a merger, exchange of capital stock, and asset acquisition. The company was founded on October 27, 2005 and is headquartered in Red Bank, NJ. | Finance |
Q Therapeutics, Inc.
Q Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman in March 2002 and is headquartered in Salt Lake City, UT. | Health Technology |
